EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Glucocorticoid discontinuation and clinical phenotypes in patients with giant cell arteritis: A retrospective cohort study from a fast track clinic

Tanja Fromberg Gorlen iD, Uffe Møller Døhn iD, Marie Celeste Heymonet iD, Jane Maestri Brittain iD, Mikkel Østergaard iD, Rasmus Sejersten Ripa iD, Peter Riis Hansen iD, Søren Jacobsen iD, Lene Terslev iD

Therapeutic Advances in Musculoskeletal Disease · 2026-08 · 18

DOI: 10.1177/1759720x261477872 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Therapeutic Advances in Musculoskeletal Disease, online erschienen am 17.08.2026. Verfasst von Tanja Fromberg Gorlen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Copenhagen Univers…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danish Rheumatism Association, Beckett-Foundation, Direktør michael hermann Nielsens Mindelegat, afd. B.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous studies have shown that many patients with giant cell arteritis (GCA) remain on glucocorticoid (GC) therapy for several years, though mostly based on older data. Identifying predictors of successful GC tapering is increasingly relevant. Objectives to 1) determine the probability of discontinuing GC treatment, 2) characterise clinical phenotypes within the GCA spectrum, and 3) their predictive value for successful GC discontinuation.

Design

A retrospective cohort study of all patients diagnosed with GCA in our fast track Clinic (FTC) between September 2018 and December 2021.

Methods

Clinical, biochemical and imaging data were obtained from patient records from the time of the FTC visit until 31.12.2023. The cumulative incidence of GC discontinuation was estimated using a competing risks model. Symptom- and laboratory-based phenotypes were identified through hierarchical cluster analysis.

Results

During the study period, 172 patients were diagnosed with GCA. At baseline, 26% had a prior diagnosis of GCA or polymyalgia rheumatica (PMR). The cumulative incidence of GC discontinuation was 10% at one year, 43% at two years, 58% at three years, and 69% at four and five years after the FTC visit, respectively. Patients with prior GCA/PMR had a lower probability of discontinuing GC treatment than those with new-onset disease. Four symptom-based and three laboratory-based phenotypic clusters were identified, but none of these variables predicted successful GC discontinuation. Multivariable Fine-Gray regression confirmed that previous GCA/PMR was an independent predictor of reduced probability of GC discontinuation.

Conclusions

In this real-world cohort, many patients required GC therapy for more than two years. The identified phenotypes did not predict treatment discontinuation. A previous diagnosis of GCA/PMR was associated with a persistent disease course.

Schlagwörter

Stichwörter der Autor:innen

fast track clinicgiant cell arteritisglucocorticoid therapy

Autor:innen und Institutionen

  • Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark.
  • Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark.
  • Copenhagen Research Centre for Autoimmune Connective Tissue Diseases (COPEACT), Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Tanja Fromberg Gorlen, Uffe Møller Døhn, Marie Celeste Heymonet, Jane Maestri Brittain, Mikkel Østergaard, Rasmus Sejersten Ripa, Peter Riis Hansen, Søren Jacobsen, Lene Terslev

Förderung

  • Danish Rheumatism Association
  • Beckett-Foundation
  • Direktør michael hermann Nielsens Mindelegat, afd. B

Zitieren

APA

Gorlen, T. F., Møller Døhn, U., Heymonet, M. C., Brittain, J. M., Østergaard, M., Ripa, R. S., Hansen, P. R., Jacobsen, S., & Terslev, L. (2026). Glucocorticoid discontinuation and clinical phenotypes in patients with giant cell arteritis: A retrospective cohort study from a fast track clinic. Therapeutic Advances in Musculoskeletal Disease, 18. https://doi.org/10.1177/1759720x261477872

Vancouver

Gorlen TF, Møller Døhn U, Heymonet MC, Brittain JM, Østergaard M, Ripa RS, et al. Glucocorticoid discontinuation and clinical phenotypes in patients with giant cell arteritis: A retrospective cohort study from a fast track clinic. Therapeutic Advances in Musculoskeletal Disease. 2026;18. doi:10.1177/1759720x261477872

BibTeX
@article{Gorlen2026,
  author = {Gorlen, Tanja Fromberg and Møller Døhn, Uffe and Heymonet, Marie Celeste and Brittain, Jane Maestri and Østergaard, Mikkel and Ripa, Rasmus Sejersten and Hansen, Peter Riis and Jacobsen, Søren and Terslev, Lene},
  title = {Glucocorticoid discontinuation and clinical phenotypes in patients with giant cell arteritis: A retrospective cohort study from a fast track clinic},
  journal = {Therapeutic Advances in Musculoskeletal Disease},
  year = {2026},
  volume = {18},
  doi = {10.1177/1759720x261477872}
}
Kostenlos starten →